Skip to content

Study · Animal study (in vivo) · mouse · 2012

3 results

Prevention of atrophic nonunion by the systemic administration of parathyroid hormone (PTH 1-34) in an experimental animal model.

Lin EA, Liu CJ, Monroy A, Khurana S, Egol KA

Journal of orthopaedic trauma1 Dec 2012Cited by 21 (Europe PMC)

PMID22932751 (opens in a new tab)DOI10.1097/bot.0b013e31826f5b9e (opens in a new tab)PepBankPUB-22932751
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with surgical femoral nonunion, PTH increased radiographic bony union compared with saline.

    In plain wordsIn mice with femoral nonunion, PTH increased bone union compared with saline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBony union at 6 weeks
    Study

    micen: not reported in source

    Surgical femoral atrophic nonunion model
    Comparator
    Saline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg daily · intraperitoneal · 14 daysAs given in this study (mice).

    Measurements

    Bony union rate
    50%
    PTH
    Bony union rate
    8%
    control

    Source sentences

    Summary
    At 6 weeks after surgery, the group treated with PTH showed higher rates of bony union (50% vs 8%; P < 0.05) as assessed by radiographic analysis.
    1 context sentence
    Summary · context
    Mice were randomized to receive either daily intraperitoneal injections of 30 μg/kg PTH 1-34 for 14 days or saline injections.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with surgical femoral nonunion, the abstract reports a significantly lower mean gap size with PTH than control.

    In plain wordsIn mice with femoral nonunion, the abstract reports a smaller fracture gap with PTH than control.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseMean fracture gap size
    Study

    micen: not reported in source

    Surgical femoral atrophic nonunion model
    Comparator
    Saline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg daily · intraperitoneal · 14 daysAs given in this study (mice).

    Source sentences

    Summary
    Mean gap size was also significantly lower in the PTH group (1.42 vs 0.36 mm in the control group; P < 0.05).
    1 context sentence
    Summary · context
    Mice were randomized to receive either daily intraperitoneal injections of 30 μg/kg PTH 1-34 for 14 days or saline injections.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In healed PTH-treated mice, histology showed cortical bridging with mature bone and relatively little callus.

    In plain wordsIn mice that healed after PTH, tissue analysis showed mature bone bridging and relatively little repair callus.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableHistologic cortical bridging
    Study

    micen: not reported in source

    Surgical femoral atrophic nonunion model
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg daily · intraperitoneal · 14 daysAs given in this study (mice).

    Source sentences

    Summary
    In contrast, healed subjects in the PTH-treated group had cortical bridging with mature bone and relatively little callus, which is consistent with primary intramembranous ossification.
    1 context sentence
    Summary · context
    Mice were randomized to receive either daily intraperitoneal injections of 30 μg/kg PTH 1-34 for 14 days or saline injections.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.